Get in Touch

Stonegate Healthcare Reviews Retinitis Pigmentosa

Key Takeaways
  • Retinitis Pigmentosa (RP) is the leading cause of visual disability and blindness in patients under 60.
  • Gene therapies, while promising, are limited in their application by disease stage and genetic mutation.
  • Small molecule photoswitches conversely hold potential to treat mid- to late-stage RP as a stand-alone drug or in combination with gene therapies.

DALLAS, TX -- December 9th, 2022 -- Stonegate Healthcare has published a new report on Retinitis Pigmentosa (RP) and the pipeline of products in development. The report follows a recent webinar with ophthalmology experts, including a leading researcher and physician, Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., Chief Development Officer of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman from the Foundation Fighting Blindness.

"There are currently more than 100 drugs in various stages of development for RP worldwide. Development of new treatments is largely being advanced by innovative biotechnology companies. This report breaks down the various approaches of gene therapy, cell therapy, optogenetics, and an emerging class of small molecule photoswitches and their potential to usher in a new era for patients.”



Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.

Key Takeaways
  • Retinitis Pigmentosa (RP) is the leading cause of visual disability and blindness in patients under 60.
  • Gene therapies, while promising, are limited in their application by disease stage and genetic mutation.
  • Small molecule photoswitches conversely hold potential to treat mid- to late-stage RP as a stand-alone drug or in combination with gene therapies.
Read Full Report on RP
Quotes
“
This report breaks down the various approaches of gene therapy, cell therapy, optogenetics, and an emerging class of small molecule photoswitches.
Shiv Kapoor — Managing Partner Healthcare at Stonegate Capital Partners
Related Bios
Shiv Kapoor
Managing Partner Healthcare at Stonegate Capital Partners
View Full Bio>>
Contacts
Stonegate Capital Partners
info@stonegateinc.com
(214) 987-4121
General